268 related articles for article (PubMed ID: 27696259)
1. Targeting the Bone Marrow Microenvironment.
Moschetta M; Kawano Y; Podar K
Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
[TBL] [Abstract][Full Text] [Related]
2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
4. Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.
Yao H; Cheng L; Chen D; Zhang Q; Qiu L; Ren SH; Dou BT; Wang H; Huang J; Fan FY
Expert Rev Anticancer Ther; 2023; 23(8):807-815. PubMed ID: 37343305
[TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
6. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
7. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Microenvironment for Treating Multiple Myeloma.
Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
[TBL] [Abstract][Full Text] [Related]
10. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
11. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma.
Ribatti D; Nico B; Vacca A
Oncogene; 2006 Jul; 25(31):4257-66. PubMed ID: 16518413
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
13. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
14. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Ho M; Xiao A; Yi D; Zanwar S; Bianchi G
Curr Oncol; 2022 Nov; 29(11):8975-9005. PubMed ID: 36421358
[TBL] [Abstract][Full Text] [Related]
15. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.
Asimakopoulos F; Hope C; Johnson MG; Pagenkopf A; Gromek K; Nagel B
J Leukoc Biol; 2017 Aug; 102(2):265-275. PubMed ID: 28254840
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow microenvironment and the identification of new targets for myeloma therapy.
Podar K; Chauhan D; Anderson KC
Leukemia; 2009 Jan; 23(1):10-24. PubMed ID: 18843284
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma.
Uckun FM
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922005
[TBL] [Abstract][Full Text] [Related]
19. Adipose, Bone, and Myeloma: Contributions from the Microenvironment.
McDonald MM; Fairfield H; Falank C; Reagan MR
Calcif Tissue Int; 2017 May; 100(5):433-448. PubMed ID: 27343063
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for multiple myeloma.
Podar K; Tai YT; Hideshima T; Vallet S; Richardson PG; Anderson KC
Expert Opin Emerg Drugs; 2009 Mar; 14(1):99-127. PubMed ID: 19249983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
